Return to homepagePandemic Pact

CHARACTERIZATION OF MPOX

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 75N91019D00024-0-759102500017-1

Grant search

Key facts

  • Disease

    mpox

  • Start & end year

    2025
    2027

  • Known Financial Commitments (USD)

    $5,583,900

  • Funder

    National Institutes of Health (NIH)

  • Research Location

    United States of America

  • Lead Research Institution

    LEIDOS BIOMEDICAL RESEARCH, INC.

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Disease pathogenesis

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

  • Mpox Research Priorities

    Clinical characterisation and management

  • Mpox Research Sub Priorities

    Promote improved understanding of the disease (including evidence synthesis)

Abstract

Since 2022, DCR and LBR have conducted monkeypox treatment trials in the Democratic Republic of Congo. This monkeypox Characterization non-severable task order complements this prior research given DCR/LBR further analyses of the PALM007 RCT results highlighted remaining monkeypox knowledge gaps, specifically related to the risk of death or severe disease from clade I monkeypox. In PALM007, patients who presented with flat/malignant lesions (as opposed to the classically appearing and evolving lesions) had an increased risk of mortality: 7/7 (100%) of those with flat lesions died compared with 3/590 (0.5%) of the remaining study participants. Patients presenting with thousands of lesions experiencing mild/moderate disease and others with prolonged disease after presenting with few lesions. It is suspected that this is likely related to host-related risk factors, however, researchers are unable to evaluate this fully retrospectively with the samples available.